| Objective To investigate the expression and its effect on prognosis of vasohibin-2(VASH-2) in breast cancer tissues. Methods Postoperative tissue specimens of 185 patients with primary breast cancer who underwent surgical treatment at the Cancer Hospital of Xinjiang Medical University from January 1, 2012 to December 31, 2013 were retrospectively analyzed. Breast cancer tissues and paraneoplastic tissues VASH-2 were detected in all patients by immunohistochemistry. Preoperative ultrasound-guided puncture of different lesions of breast cancer was performed by immunohistochemistry to analyze the expression of VASH-2 protein in breast cancer lesions with abundant blood flow and breast cancer lesions with lack of blood supply. The relationship between VASH-2 high expression and clinicopathological features was analyzed. The influence of high VASH——2 expression on 5-year progression-free(PFS) survival of patients with breast cancer was analyzed by Kaplan-Meier method. Results The high expression rate of VASH-2 in breast cancer tissues was 52.43% (97/185), while that in paraneoplastic tissues was 27.03% (50/185), and the difference between the two groups was statistically significant (χ2=24.933, P<0.001). The high expression rate of VASH-2 was 60.82% (59/97) in breast cancer tissues with rich blood supply, and 38.64% (34/88) in breast cancer tissues with poor blood supply, with statistical significance (χ2=9.087, P<0.05).VASH-2 high staining was not associated with age, lymph node metastasis, tumor stage, ER expression, menopause or not, and tumor cytology grade (P>0.05), but with mass size, molecular staging, and CerbB-2 expression (P<0.05).The 5-year PFS of breast cancer with VASH-2 low expression was better than that of VASH-2 high expression, and the difference was statistically significant (χ2=5.635, P<0.05). Conclusions VASH-2 is highly expressed in breast cancer tissues and is positively correlated with angiogenesis of breast cancer, and its expression level can provide reference for prognosis of breast cancer. |
